Tag: AF ablation
Mapping integrated PFA catheter produces “never before” seen outcomes for the...
This article was sponsored by Biosense Webster
“The simplicity, the efficacy and the safety” of pulsed field ablation (PFA) in the treatment of atrial fibrillation...
EHRA 2023: Novel score predicts heart failure following atrial fibrillation ablation
A score based on four readily available clinical and imaging parameters identifies the heart failure patients who benefit most from atrial fibrillation (AF) ablation, according...
Analysis of NIS database shows racial disparities in atrial fibrillation outcomes...
Using data from a large and “nationally representative” sample of the US population, a recent study is the first—the authors posit—to demonstrate racial differences...
Early rhythm control aids recurrent stroke prevention in patients with AF
Early rhythm control one year after atrial fibrillation (AF) diagnosis has been found to be beneficial in preventing recurrent stroke in patients with incident...
Inpatient AF ablation associated with early mortality and post-procedure complications, study...
Atrial fibrillation (AF) ablation carried out in an inpatient setting is associated with higher rates of early mortality and subsequent complications when compared with...
Ablation as first-line treatment cuts AF progression compared to antiarrhythmic drugs
Ablation as a first-line treatment for atrial fibrillation (AF) disease is associated with significantly better clinical outcomes than starting with antiarrhythmic drugs.
These were the...
Hot balloon ablation and cryoballoon ablation deemed effective for AF treatment
Both cryoballoon ablation (CBA) and hot balloon ablation (HBA) are effective treatment options for atrial fibrillation (AF), however, patients treated with HBA are more...
Contact force-guided ablation for typical atrial flutter does not reduce recurrent...
Contact-force (CF)-guided ablation to treat typical atrial flutter does not reduce recurrent atrial arrhythmia at 12 months follow-up, in comparison to ablation blinded for...
CardioFocus submits HeartLight X3 PMA application to FDA
CardioFocus has submitted a pre-market approval (PMA) supplement to the US Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for...
Heartlight X3 gains European CE Mark
CardioFocus has announced the European CE Mark approval for its HeartLight X3 endoscopic ablation system, used in the treatment of atrial fibrillation.
The HeartLight X3 system...
Biomarkers may predict AF after catheter ablation
Researchers have identified a combination of serum biomarkers that is independently associated with higher prevalence of atrial fibrillation, and with increased incidence and recurrence...
Results of CASTLE-AF trial published: catheter ablation better than conventional drug...
The results of the CASTLE-AF study, published today in the New England Journal of Medicine, show that patients treated with radiofrequency catheter ablation rather than...
Repeat ablation with contact force sensing “does not necessarily guarantee a...
Preliminary results from the ABLATOR observational registry have shown similar success rates (around 58%) in first time ablation and repeat ablation for persistent atrial...
CardioFocus receives approval for HeartLight Endoscopic Ablation System in Japan
CardioFocus has announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation...
Advancements in Persistent AF Ablation: New Clinical Evidence and Techniques
This webinar has been sponsored by Medtronic.
Watch the recent webinar on persistent Atrial Fibrillation (AF) ablation with Prof. Schilling (St. Barts, London), Prof. de...
First US commercial atrial fibrillation procedure with HeartLight system performed at...
CardioFocus has announced the first commercial US procedure using its HeartLight Endoscopic Ablation system for the treatment of patients with paroxysmal atrial fibrillation (AF)...